Stay updated on ADG116 Combo With Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the ADG116 Combo With Pembrolizumab in Solid Tumors Clinical Trial page.

Latest updates to the ADG116 Combo With Pembrolizumab in Solid Tumors Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0; the study record content remains unchanged.SummaryDifference0.1%

- Check22 days agoChange DetectedA banner announces that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” under Executive Order 14434.SummaryDifference0.8%

- Check29 days agoChange DetectedThe ClinicalTrials.gov site footer revision changes from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check36 days agoChange DetectedThe website’s displayed software revision changed from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check57 days agoChange DetectedA new revision entry (v3.7.0) was added to the record history, replacing the previous v3.6.6. This reflects an update to the study record's metadata.SummaryDifference0.1%

- Check79 days agoChange DetectedThe record history adds a new revision entry (v3.6.6) and removes the previous revision (v3.6.5) from the visible history, updating the page's version trail.SummaryDifference0.1%

Stay in the know with updates to ADG116 Combo With Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ADG116 Combo With Pembrolizumab in Solid Tumors Clinical Trial page.